恒瑞医药(600276.SH)：获得SHR-2906注射液临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of SHR-2906 injection, a self-developed therapeutic biological product aimed at regulating glucose and lipid metabolism and controlling weight [1] Group 1: Product Development - SHR-2906 injection is expected to synergistically reduce energy intake and promote energy expenditure, improving the metabolic environment in the body and potentially offering clinical efficacy in treating overweight and obesity [1] - There are currently no similar drugs approved for market use domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-2906 injection project has reached approximately 17.06 million yuan [1]